Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 2:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 15,039 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Vascular Clear all

Conditions: Diabetic Foot Ulcer
Interventions: Amnio Excel + weekly, Amnio Excel + max every 2 weeks; Device
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 21 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Diabetes Mellitus, Non-Insulin-Dependent, Hypertensive Disease
Interventions: Liraglutide or Placebo; Drug
Lead sponsor: Tulane University School of Medicine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Hereditary Angioedema
Interventions: C1 esterase inhibitor [human] (C1INH-nf), Placebo (saline); Biological · Drug
Lead sponsor: Shire; Industry
Eligibility: 6 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 16
States / cities: Scottsdale, Arizona • San Diego, California • Walnut Creek, California + 13 more

Conditions: Brain Neoplasms, Malignant, Brain Neoplasms, Benign, Malignant Meningioma, Glioblastoma Multiforme, Anaplastic Astrocytoma
Interventions: Pioglitazone; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Surgical Procedure, Unspecified
Interventions: Microsurgical Training Models; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Cystic Fibrosis
Interventions: sildenafil, placebo; Drug
Lead sponsor: National Jewish Health; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Vascular Closure
Interventions: Mynx Vascular Closure Device, AngioSeal Vascular Closure Device; Device
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Peripheral Arterial Disease
Interventions: Bupivacaine liposome, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Eau Claire, Wisconsin

Conditions: Coronary Artery Disease
Interventions: Bioresorbable Vascular Scaffold, Drug Eluting Stent; Device
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Falls Church, Virginia

Conditions: Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions: alemtuzumab, graft-versus-tumor induction therapy, rituximab, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, allogeneic bone marrow transplantation; Biological · Drug · Procedure
Lead sponsor: Northside Hospital, Inc.; Other
Eligibility: 40 Years to 72 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Infertility
Interventions: Acupuncture; Procedure
Lead sponsor: Texas Tech University Health Sciences Center; Other
Eligibility: 21 Years to 42 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Cerebrovascular Accident
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Multiple Myeloma
Interventions: Laboratory Biomarker Analysis, Lenalidomide, Melphalan, Prednisone, Quality-of-Life Assessment, Thalidomide; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2027
U.S. locations: 389
States / cities: Mobile, Alabama • Scottsdale, Arizona • Fort Smith, Arkansas + 255 more

Conditions: CLL / SLL, CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma), Marginal Zone Lymphoma(MZL), Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia
Interventions: Lonitoclax (ZE50-0134); Drug
Lead sponsor: Lomond Therapeutics Holdings, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: Louisville, Kentucky • Chapel Hill, North Carolina • Cincinnati, Ohio + 2 more

Conditions: Pulmonary Vein Stenosis
Interventions: LA transplant; Procedure
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Up to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Stroke, Ischemic, Intracranial Atherosclerosis, Posterior Circulation Brain Infarction
Interventions: we are aiming to develop a Scoring system based on certain variables derived from both groups; Other
Lead sponsor: Sohag University; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Abdominal Aortic Aneurysm
Interventions: Endovascular AAA repair with InCraft®; Device
Lead sponsor: Cordis US Corp.; Industry
Eligibility: 20 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Acute Coronary Syndrome
Interventions: Sponsor MCG device (CardiAQ); Device
Lead sponsor: SB Technology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Rochester, Minnesota • New York, New York

Conditions: Kidney Failure, Chronic, Cardiovascular Disease, Arteriosclerosis
Interventions: Hydroxychloroquine, Matching Placebo; Drug · Other
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Little Rock, Arkansas • Gainesville, Florida

Conditions: Stenosis of Vascular Prosthetic Devices, Implants and Grafts
Interventions: FLAIR Endovascular Stent Graft, PTA; Device · Procedure
Lead sponsor: C. R. Bard; Industry
Eligibility: 21 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Bamberg, South Carolina

Conditions: Pulmonary Arterial Hypertension
Interventions: Fluoxetine; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 16 Years to 75 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hemodialysis Complication, Fluid Overload, Dialysis Disequilibrium, Intra-dialytic Hypotension, Hypertension
Interventions: Dialysate Sodium Lowering; Other
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertension
Interventions: fenoldopam, Placebo; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 70 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Subarachnoid Hemorrhage, Aneurysmal, Vasospasm, Cerebral
Interventions: Acetazolamide; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Search by objective public record fields.

Characterization of AmnioExcel Plus in Two Treatment Paradigms

To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study

C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks

Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Treating Patients With Brain Tumors

Bucatini Pasta, Japanese Shirataki Konjac Noodles, and Artificial Vessels: In Search of the Ideal Low-cost Vessel Simulator for Microsurgical Education

Evaluation and Treatment of Pulmonary Vascular Disease in Moderate to Severe CF

Patient Comfort With Vascular Closure

A Study of Loco-Regional Liposomal Bupivacaine Injection

Thrombogenicity Assessment in Patients Treated With Bioresorbable Vascular Scaffolds

Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer

Effect of Acupuncture on Vascular Biomarkers and Psychological Well-Being of Women Undergoing IVF

Electrical Stimulation to Improve Hand Function in Patients With Chronic Stroke

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies

Allogeneic Left Atrial and Pulmonary Vein Transplant for Pulmonary Vein Stenosis

Predictors of Intracranial Atherosclerotic Disease in Posterior Circulation: a Cohort Study

A Multicenter, Open Label, Prospective, Non-randomized Study of the InCraft® Stent Graft System in Subjects With Abdominal Aortic Aneurysms (INSPIRATION)

A Prospective Research Investigation of Ischemia Using MCG

Hydroxychloroquine in Cardiovascular Disease in Patients With Chronic Kidney Disease: A Proof of Concept Study

Post-Approval Study for the FLAIR Endovascular Stent Graft

Safety and Efficacy of Fluoxetine in Pulmonary Arterial Hypertension

Dialysate Sodium Lowering Trial

Effect of Gene Variants on Dopamine Receptor Natriuretic Responses

Acetazolamide Challenge With Perfusion in the Prediction of Cerebral Vasospasm